. 2022 Jul 10;14(14):3358. doi: 10.3390/cancers14143358

Table 7.

The highlights of this study at a glance.

Highlights of This Study
The analysis of the merged microarray meta-dataset, comprising of 410 BCa and 196 healthy urinary bladder tissue samples from 18 independent datasets, revealed 815 robust differentially expressed genes (DEGs). A total of 61 key hub genes resulted from DEG-based protein–protein interaction (PPI) and weighted gene co-expression (WGCNA) network analyses. A subset of key hub genes, namely AURKB, CCNB2, CDC45, CDCA8, CDT1, CENPU, COL3A1, GINS2, KIF20A, MCM4, PBK, PLK4, SDC1, SPP1, TOP2A, TTK, and UBE2C, were found to be differentially expressed in the urine of BCa patients. A subset of key hub genes, namely ANXA5, ASPM, CD34, CDC20, CDT1, COL4A5, COL6A1, ECT2, HJURP, MCM2, and VEGFA, were found to be differentially expressed in the blood plasma of BCa patients. Bioinformatics tools and machine learning techniques were utilized to reveal and assess the diagnostic, prognostic, and predictive value of the identified key hub genes. A three-gene signature prognostic model for BCa patients, including COL3A1, FOXM1, and PLK4, was built and demonstrated high performance. A six-gene signature predictive model regarding MIBC patients’ response to neoadjuvant chemotherapy, including ANXA5, CD44, NCAM1, SPP1, CDCA8, and KIF14, was developed and showed satisfactory performance. Overall, nine genes, namely ANXA5, CDT1, COL3A1, SPP1, VEGFA, CDCA8, HJURP, TOP2A, and COL6A1, were identified as potential prognostic and therapeutic target biomarkers for BCa, they were immunohistochemically validated using Human Protein Atlas (HPA), and were bibliographically analyzed.

Highlights of This Study

The analysis of the merged microarray meta-dataset, comprising of 410 BCa and 196 healthy urinary bladder tissue samples from 18 independent datasets, revealed 815 robust differentially expressed genes (DEGs).
A total of 61 key hub genes resulted from DEG-based protein–protein interaction (PPI) and weighted gene co-expression (WGCNA) network analyses.
A subset of key hub genes, namely AURKB, CCNB2, CDC45, CDCA8, CDT1, CENPU, COL3A1, GINS2, KIF20A, MCM4, PBK, PLK4, SDC1, SPP1, TOP2A, TTK, and UBE2C, were found to be differentially expressed in the urine of BCa patients.
A subset of key hub genes, namely ANXA5, ASPM, CD34, CDC20, CDT1, COL4A5, COL6A1, ECT2, HJURP, MCM2, and VEGFA, were found to be differentially expressed in the blood plasma of BCa patients.
Bioinformatics tools and machine learning techniques were utilized to reveal and assess the diagnostic, prognostic, and predictive value of the identified key hub genes.
A three-gene signature prognostic model for BCa patients, including COL3A1, FOXM1, and PLK4, was built and demonstrated high performance.
A six-gene signature predictive model regarding MIBC patients’ response to neoadjuvant chemotherapy, including ANXA5, CD44, NCAM1, SPP1, CDCA8, and KIF14, was developed and showed satisfactory performance.
Overall, nine genes, namely ANXA5, CDT1, COL3A1, SPP1, VEGFA, CDCA8, HJURP, TOP2A, and COL6A1, were identified as potential prognostic and therapeutic target biomarkers for BCa, they were immunohistochemically validated using Human Protein Atlas (HPA), and were bibliographically analyzed.